Rank Discriminants for Predicting Phenotypes from RNA Expression

Bahman Afsari*, Ulisses Braga Neto† and Donald Geman*

Department of Electrical and Computer Engineering
Whiting School of Engineering
Johns Hopkins University
bahman@jhu.edu

Department of Electrical and Computer Engineering
Dwight Look College of Engineering
Texas A&M University
ub@ieee.org

Department of Applied Mathematics and Statistics
Whiting School of Engineering
Johns Hopkins University
geman@jhu.com

Abstract: Statistical methods for analyzing large-scale biomolecular data are commonplace in computational biology. A notable example is phenotype prediction from gene expression data, for instance detecting human cancers, differentiating subtypes, and predicting clinical outcomes. Still, clinical applications remain scarce. One reason is that the complexity of the decision rules that emerge from standard statistical learning impedes biological understanding, in particular any mechanistic interpretation. Here we explore decision rules for binary classification utilizing only the ordering of expression among several genes; the basic building blocks are then two-gene expression comparisons. The simplest example, just one comparison, is the TSP classifier, which has appeared in a variety of cancer-related discovery studies. Decision rules based on multiple comparisons can better accommodate class heterogeneity and thereby increase accuracy, and might provide a link with biological mechanism. We consider a general framework (“rank-in-context”) for designing discriminant functions, including a data-driven selection of the number and identity of the genes in the support (“context”). We then specialize to two examples: voting among several pairs and comparing the median expression in two groups of genes. Comprehensive experiments assess accuracy relative to other, more complex, methods, and reinforce earlier observations that simple classifiers are competitive.

Keywords and phrases: Cancer classification, Gene expression, Rank discriminant, Order statistics.

1. Introduction

Statistical methods for analyzing high-dimensional biomolecular data generated with high-throughput technologies permeate the literature in computational biology. Prominent examples are genome-wide association studies based on DNA

*Supported by NIH-NCRR Grant UL1 RR 025005.
†Supported by the National Science Foundation through NSF award CCF-0845407.
sequence data, and gene network inference and genotype-to-phenotype prediction based on gene microarray data. Such analyses have uncovered a great deal of information about biological processes, such as important mutations and lists of “marker genes” associated with common diseases (Jones et al. [2008], Thomas et al. [2007]) and key interactions in transcriptional regulation (Auffray [2007], Lee et al. [2008]).

The work here is about learning classifiers that can distinguish between cellular phenotypes from mRNA transcript levels collected from cells in assayed tissue. The primary focus is the structure of the prediction rules. This is largely motivated by applications involving genetic diseases such as cancer, where malignant phenotypes arise from the net effect of interactions among multiple genes and other molecular agents within biological networks. Moreover, the resulting perturbations in signaling pathways can be detected and quantified with mRNA counts estimated from microarrays. In principle, therefore, statistical methods can enhance our understanding by detecting the presence of disease (e.g., “tumor” vs “normal”), discriminating among cancer sub-types (e.g., “GIST” vs “LMS” or “BRCA1 mutation” vs “no BRCA1 mutation”) and predicting clinical outcomes (e.g., “poor prognosis” vs “good prognosis”).

Nonetheless, the applications to biomedicine, specifically the implications for clinical practice, are widely acknowledged to remain limited; see Altman et al. [2011], Marshall [2011], Evans et al. [2011] and the discussion in Winslow et al. [2012]. One barrier is the study-to-study diversity in reported prediction accuracies and “signatures” (lists of discriminating genes). Some of this variation can be attributed to the over-fitting that results from the unfavorable ratio of the sample size to the number of potential biomarkers, i.e., the infamous “small n, large d” dilemma. Typically, the number of samples (chips, profiles, patients) per class is $n = 10^2 - 10^3$ whereas the number of features (exons, transcripts, genes) is usually $d = 10^3 - 50,000$; Table 1 displays $n_0, n_1, d$ for twenty-one publicly available datasets involving two phenotypes.

However, complex decision rules are perhaps the central obstacle to mature applications. The classification methods applied to biological data were usually designed for other purposes, such as improving statistical learning or applications to vision and speech, with little emphasis on transparency. Specifically, the rules generated by nearly all standard, off-the-shelf techniques applied to genomics data, such as neural networks (Bicciato et al. [2003], Bloom et al. [2004], Khan et al. [2001]), multiple decision trees (Boulesteix et al. [2003], Zhang et al. [2003]), support vector machines (Peng et al. [2003], Yeang et al. [2001]), boosting (Qu et al. [2002], Dettling and Buhlmann [2003]), and linear discriminant analysis (Guo et al. [2007], Tibshirani et al. [2002]), usually involve nonlinear functions of hundreds or thousands of genes, a great many parameters, and are therefore too complex to characterize biologically.

In contrast, follow-up studies, for instance independent validation or therapeutic development, are usually based on a relatively small number of biomarkers whose concentrations can then be assayed with high-resolution methods such as RT-PCR. This usually also requires an understanding of the role of the genes and gene products in the context of molecular pathways. Ideally,
Table 1

The Datasets: Twenty-one datasets involving two disease-related phenotypes (e.g., cancer vs normal tissue or two cancer sub-types), illustrating the “small n, large d” situation. Shown are the samples sizes for the two classes and the number d of features (probes on the microarray). The more pathological phenotype is labeled as Class 1 when this information is available.

| Study | Class 0 (size) | Class 1 (size) | Probes d | Reference |
|-------|----------------|----------------|----------|-----------|
| D1    | Colon          | Normal (22)    | Tumor (40)| 2000      | Alon et al. [1999] |
| D2    | BRCA1          | non-BRCA1 (93) | BRCA1 (25)| 1658      | Lin et al. [2009] |
| D3    | CNS            | Classic (25)   | Desmoplastic (9) | 7129 | Pomeroy et al. [2002] |
| D4    | DLBLCL         | DLBLCL (58)    | FL (19)  | 7129      | Shipp et al. [2002] |
| D5    | Lung           | Mesothelioma (150) | ADCS (31) | 12533 | Gordon et al. [2002] |
| D6    | Marfan         | Normal (41)    | Marfan (60) | 4123 | Yao et al. [2007] |
| D7    | Crohn’s        | Normal (42)    | Crohn’s (59) | 22283 | Burczynski et al. [2006] |
| D8    | Sarcoma        | GIST (37)      | LMS (31) | 43931 | Price et al. [2007] |
| D9    | Squamous       | Normal (22)    | Head-Neck Cancer (22) | 12625 | Kuriakose et al. [2004] |
| D10   | GCM            | Normal (90)    | Tumor (190) | 16063 | Ramaswamy et al. [2001] |
| D11   | Leukemia 1     | ALL (25)       | AML (47)  | 7129      | Golub et al. [1999] |
| D12   | Leukemia 2     | AML1 (24)      | AML2 (24) | 12564 | Armstrong et al. [2002] |
| D13   | Leukemia 3     | ALL(710)       | AML (501) | 19896 | Kohlmann et al. [2008] |
| D14   | Leukemia 4     | Normal (138)   | AML (463) | 19896 | Mills et al. [2009] |
| D15   | Prostate 1     | Normal (50)    | Tumor (52) | 12600 | Singh et al. [2002] |
| D16   | Prostate 2     | Normal (38)    | Tumor (50) | 12625 | Stuart et al. [2004] |
| D17   | Prostate 3     | Normal (9)     | Tumor (24) | 12626 | Welsh et al. [2001] |
| D18   | Prostate 4     | Normal (25)    | Primary (65) | 12619 | Yao et al. [2004] |
| D19   | Prostate 5     | Primary (25)   | Metastatic (65) | 12558 | Yao et al. [2004] |
| D20   | Breast 1       | ER-positive (61) | ER-negative(36) | 16278 | Enerly et al. [2011] |
| D21   | Breast 2       | ER-positive(127) | ER-negative(80) | 9760 | Buffa et al. [2011] |

The decision rules could be interpreted mechanistically, for instance in terms of transcriptional regulation, and be robust with respect to parameter settings. Consequently, what is notably missing from the large body of work applying classification methodology to computational genomics is a solid link with potential mechanism, which seem to be a necessary condition for “translational medicine” (Winslow et al. [2012]) i.e., drug development and clinical diagnosis.

Needless to say, accuracy is also necessary, but the accuracy of many of the methods mentioned above is already high enough to be of potential clinical value for many important phenotype distinctions. And whereas it has become commonplace to follow methodological development and illustrations on real data with a discussion of the genes appearing in the support (“signature”) of the classifier, often in terms of their “enrichment” for specific biological process and molecular functions, this does not substitute for providing a potential mechanistic characterization of the decision rules in terms of biochemical interactions or specific regulatory motifs.

These translational objectives, and small-sample issues, argue for limiting the number of parameters and introducing strong biases. The two principal objectives for the family of classifiers described here are:

- Use elementary and parameter-free building blocks to assemble a classifier which is determined by its support.
- Demonstrate that these can be as discriminating as those that emerge from the most powerful methods in statistical learning.

The building blocks we choose are two-gene comparisons, which we think
of as “biological switches” which can be directly related to regulatory “motifs” or other properties of transcriptional networks. The decision rules are then determined by expression orderings. However, explicitly connecting statistical classification and molecular mechanism for particular diseases is a major challenge and is well beyond the scope of this paper; by our construction we are anticipating our longer-term goal of incorporating mechanism, and some comments on the relationship between comparisons and regulation appear in the concluding section.

As concerns our second objective, we measure the performance of our comparison-based classifiers relative to two popular alternatives, namely support vector machines and PAM (Tibshirani et al. [2002]), a variant of linear discriminant analysis, where the “metric” chosen is the estimated error in multiple runs of ten-fold cross validation for each of the twenty-one real datasets in Table 1. Whereas a comprehensive simulation study could be conducted, for example along the lines of those in Guo et al. [2005], Zhang et al. [2006] and Fan and Fan [2008] based on Gaussian models of microarray data, our intention is different: show that even when the number of parameters is small, in fact the decision rule is determined by the support, the accuracy in cross-validation on real data is no worse than with currently available classifiers.

More precisely, all the classifiers studied in this paper are based on a general rank discriminant \( g(X; \Theta) \), a real-valued function on the ranks of \( X \) over a (possibly ordered) subset of genes \( \Theta \), called the context of the classifier. We are searching for characteristic perturbations in this ordering from one phenotype to another. The TSP classifier is the simplest example (see Section 2), and the decision rule is illustrated in Figure 1. This data set has expression profiles for two kinds of gastrointestinal cancer (gastrointestinal stromal-GIST, leiomyosarcoma-LMS) which are difficult to distinguish clinically but require very different treatments (Price et al. [2007]). Each point on the x-axis corresponds to a sample, and the vertical dashed line separates the two phenotypes. The y-axis represents expression; as seen, the “reversal” of the ordering of the expressions of the two genes identifies the phenotype except in two samples.

Evidently, a great deal of information may be lost by converting to ranks, particularly if the expression values are high resolution. But there are technical advantages to basing prediction on ranks, including reducing study-to-study variations due to data normalization and pre-processing; for example, rank-based methods are evidently invariant to general monotone transformations of the original expression values, such as the widely-used quantile normalization (Bolstad et al. [2004]). This enables combining inter-study microarray data without the need to perform data normalization, thereby increasing sample size.

However, our principal motivation is complexity reduction: severely limiting the number of variables and parameters, and in fact introducing what we call rank-in-context (RIC) discriminants which depend on the training data only through the context. The classifier \( f \) is then defined by thresholding \( g \). This implies that, given a context \( \Theta \), the RIC classifier corresponds to a fixed decision boundary, in the sense that it does not depend on the training data. This sufficiency property helps to reduce variance by rendering the classifiers rela-
tively insensitive to small disturbances to the ranks of the training data and is therefore especially suitable to small-sample settings. Naturally, the performance critically depends on the appropriate choice of $\Theta$. We propose a simple yet powerful procedure to select $\Theta$ from the training data, partly inspired by the principle of analysis of variance and involving the sample means and sample variances of the empirical distribution of $g$ under the two classes. In particular, we do not base the choice directly on minimizing error.

We consider two examples of the general framework. The first is a new method for learning the context of $KTSP$, a previous extension of $TSP$ to a variable number of pairs. The decision rule of the $KTSP$ classifier is the majority vote among the top $k$ pairs of genes, illustrated in Figure 1 for $k = 10$ for the same dataset as above. In previous statistical and applied work (Tan et al. [2005]), the parameter $K$ (the number of comparisons) was determined by an inner loop of cross-validation, which is subject to over-fitting with small samples. We also propose comparing the median of expression between two sets of genes; this $Top$-$Scoring$ $Median$ ($TSM$) rule is also illustrated in Figure 1; as can be seen, the difference of the medians generally has a larger “margin” than in the special case of singleton sets, i.e., $TSP$. A summary of all the methods is given in Table 2.

After reviewing related work in the following section, in Section 3 we present the classification scenario, propose our general statistical framework, and focus on two examples: $KTSP$ and $TSM$. The experimental results are in Section 4, where comparisons are drawn, and we conclude with some discussion about the underlying biology in Section 5.

2. Previous and Related Work

Our work builds on previous studies analyzing transcriptomic data solely based on relative expression, more precisely the orderings among the expressions of a small number of transcripts. This methodology was designed to promote invariance to data normalization and transparency of the decision rules. The simplest example, the Top-Scoring Pair ($TSP$) classifier, was introduced in Geman et al. [2004] and is based on two genes. Various extensions and illustrations appeared in Xu et al. [2005], Lin et al. [2009], Tan et al. [2005]. Applications to phenotype classification include differentiating between stomach cancers (Price et al. [2007]), predicting treatment response in breast cancer (Weichselbaum et al. [2008]) and acute myeloid leukemia (Raponi et al. [2008]), detecting BRCA1 mutations (Lin et al. [2009]), grading prostate cancers (Zhao et al. [2010]), and separating diverse human pathologies assayed through blood-borne leukocytes (Edelman et al. [2009]).

In Geman et al. [2004] and subsequent papers about $TSP$, the discriminating power of each pair of genes $i, j$ was measured by the absolute difference between the probabilities of the event that gene $i$ is expressed more than gene $j$ in the two classes. These probabilities were estimated from training data and (binary) classification resulted from voting among all top-scoring pairs. In Xu et al.
Fig 1. Results of three rank-based classifiers for differentiating two cancer subtypes, GIST and LMS. The training set consists of 37 GIST samples and 31 LMS samples (separated by the vertical dashed line); each sample provides measurements for 43,931 transcripts. **TSP:** Expression values for the two genes selected by the TSP algorithm. **KTSP:** The number of votes for each class among the $K = 10$ pairs of genes selected by KTSP algorithm. **TSM:** Median expressions of two sets of genes selected by the TSM algorithm.
In 2005 a secondary score was introduced which provides a unique top-scoring pair. In addition, voting was extended to the $k$ highest-scoring pairs of genes. The motivation for this KTSP classifier and other extensions (Tan et al. [2005], Anderson et al. [2007], Xu et al. [2007]) is that more genes may be needed to detect cancer pathogenesis, especially if the principle objective is to characterize as well as recognize the process. Finally, in a precursor to the work here (Xu et al. [2007]), the two genes in TSP were replaced by two equally-sized sets of genes and the average ranks were compared. Since the direct extension of TSP score maximization was computationally impossible, and likely to badly over-fit the data, the sets were selected by splitting top-scoring pairs and repeated random sampling. Although ad hoc, this further demonstrated the discriminating power of rank statistics for microarray data.

Finally, there is some related work about ratios of concentrations (which are natural in chemical terms) for diagnosis and prognosis. That work is not rank-based but retains invariance to scaling. Golub et al. [1999] distinguished between malignant pleural mesothelioma (MPM) and adenocarcinoma (ADCA) of the lung by combining multiple ratios into a single diagnostic tool, and Ma et al. [2004] found that a two-gene expression ratio derived from a genome-wide, oligonucleotide microarray analysis of estrogen receptor (ER)-positive, invasive breast cancers predicts tumor relapse and survival in patients treated with tamoxifen, which is crucial for early-stage breast cancer management.

3. Rank-In-Context Classification

In this section, we introduce a general framework for rank-based classifiers using comparisons among a limited number of gene expressions, called the context. In addition, we describe a general method to select the context, which is inspired by the analysis of variance paradigm of classical statistics. These classifiers have the property that they depend on the sample data solely through the context selection; in other words, given the context, the classifiers have a fixed decision boundary and do not depend on the training data. For example, as will be seen in later sections, the Top-Scoring Pair (TSP) classifier is RIC. Once a pair of genes (i.e., the context) is specified, the TSP decision boundary is fixed, and corresponds to a 45-degree line going through the origin in the feature space defined by the two genes. This confers to RIC classifiers a minimal-training property, which makes them insensitive to small disturbances to the ranks of the training data, reducing variance and overfitting, and rendering them especially suitable to small-sample settings. We will demonstrate the general RIC framework with two specific examples, namely the previously introduced KTSP classifier based on majority voting among comparisons (Tan et al. [2005]), as well as a new classifier based on the comparison of the medians, the Top-Scoring Medians (TSM) classifier.
3.1. RIC Discriminant

Let \( X = (X_1, X_2, \ldots, X_d) \) denote the expression values of \( d \) genes on an expression microarray. Our objective is to use \( X \) to distinguish between two conditions or phenotypes for the cells in the assayed tissue, denoted \( Y = 0 \) and \( Y = 1 \).

A classifier \( f \) associates a label \( f(X) \in \{0, 1\} \) with a given expression vector \( X \). Practical classifiers are inferred from training data, consisting of i.i.d. pairs \( S_n = \{(X^{(1)}, Y^{(1)}), \ldots, (X^{(n)}, Y^{(n)})\} \).

The classifiers we consider in this paper are all defined in terms of a general rank-in-context discriminant \( g(X; \Theta(S_n)) \), which is defined as a real-valued function on the ranks of \( X \) over a subset of genes \( \Theta(S_n) \subset \{1, \ldots, d\} \), which is determined by the training data \( S_n \) and is called the context of the classifier (the order of indices in the context may matter). Such discriminants are called rank-in-context because they depend on the training data only through the context.

The corresponding RIC classifier \( f \) is defined by

\[
    f(X; \Theta(S_n)) = \mathbb{I}(g(X; \Theta(S_n)) > t) = \begin{cases} 
    1, & g(X; \Theta(S_n)) > t \\
    0, & \text{otherwise},
    \end{cases}
\]  

(3.1)

where \( \mathbb{I}(E) \) denotes the indicator variable of event \( E \). The threshold parameter \( t \) can be adjusted to achieve a desired specificity and sensitivity (see Section 3.4 below); otherwise, one usually sets \( t = 0 \). For simplicity we will write henceforth \( \Theta \) instead of \( \Theta(S_n) \), with the implicit understanding that in RIC classification \( \Theta \) is selected from the training data \( S_n \).

We will consider in this section two families of RIC classifiers. The first example is the \( k \)-Top Scoring Pairs (KTSP) classifier, which is a majority voting rule among \( k \) pairs of genes (Tan et al. [2005]); KTSP was the winning entry of the International Conference in Machine Learning and Applications (ICMLA) 2008 challenge for micro-array classification (Geman et al. [2008]). Here, the context is partitioned into a set of gene pairs \( \Theta = \{(i_1, j_1), \ldots, (i_k, j_k)\} \), where \( k \) is a positive odd integer, in such a way that all pairs are disjoint, i.e., all \( 2k \) genes are distinct. The RIC discriminant is given by:

\[
    g_{KTSP}(X; (i_1, j_1), \ldots, (i_k, j_k)) = \sum_{r=1}^{k} \left[ \mathbb{I}(X_{i_r} < X_{j_r}) - \frac{1}{2} \right].
\]  

(3.2)

This KTSP RIC discriminant simple counts positive and negative “votes” in favor of ascending or descending ranks, respectively. The KTSP classifier is given by (3.1), with \( t = 0 \), which yields

\[
    f_{KTSP}(X; (i_1, j_1), \ldots, (i_k, j_k)) = \mathbb{I} \left( \sum_{r=1}^{k} \mathbb{I}(X_{i_r} < X_{j_r}) > \frac{k}{2} \right). 
\]  

(3.3)

The KTSP classifier is thus a majority-voting rule: it assigns label 1 to the expression profile if the number of ascending ranks exceeds the number of descending ranks in the context. The choice of odd \( k \) avoids the possibility of a tie in the
vote. If \( k = 1 \), then the KTSP classifier reduces to \( f_{\text{TSP}}(X; (i, j)) = I(X_i < X_j) \), the Top-Scoring Pair (TSP) classifier (Geman et al. [2004]).

The second example of an RIC classifier we propose is the Top Scoring Median (TSM) classifier, which simply compares the median rank of two sets of genes. The median rank has the advantage that for any individual sample the median is the value of one of the genes. Hence, in this sense, a comparison of medians for a given sample is equivalent to the comparison of two gene expressions, as in the TSP decision rule. Here, the context is partitioned into two sets of genes, \( \Theta = \{G_k^+, G_k^-\} \), such that \( |G_k^+| = |G_k^-| = k \), where \( k \) is again a positive odd integer, and \( G_k^+ \) and \( G_k^- \) are disjoint, i.e., all \( 2k \) genes are distinct. Let \( R_i \) be the rank of \( X_i \) in the context \( \Theta = G_k^+ \cup G_k^- \), such that \( R_i = j \) if \( X_i \) is the \( j \)th smallest value among the gene expression values indexed by \( \Theta \). The RIC discriminant is given by:

\[
g_{\text{TSM}}(X; G_k^+, G_k^-) = \text{med}_{j \in G_k^+} R_j - \text{med}_{i \in G_k^-} R_i. \tag{3.4}
\]

where “med” denotes the median operator. The TSM classifier is then given by (3.1), with \( t = 0 \), which yields

\[
f_{\text{TSM}}(X; G_k^+, G_k^-) = I\left(\text{med}_{j \in G_k^+} R_j > \text{med}_{i \in G_k^-} R_i\right). \tag{3.5}
\]

Therefore, the TSM classifier outputs 1 if the median of ranks in \( G_k^+ \) exceeds the median of ranks in \( G_k^- \), and 0 otherwise — notice that this is equivalent to comparing the medians of the raw expression values directly. We remark that an obvious variation would be to compare the average rank rather than the median rank — this in fact corresponds to the “TSPG” approach defined in Xu et al. [2007], except that in that study, the context for TSPG was selected by splitting a fixed number of TSPs. We observed that the performances of the mean-rank and median-rank classifiers are similar, with a slight superiority of the median-rank (data not shown).

### 3.2. Criterion for Context Selection

The performance of RIC classifiers critically depends on the appropriate choice of the context \( \Theta \subset \{1, \ldots, d\} \). We propose a simple yet powerful procedure to select \( \Theta \) from the training data \( S_n \). To motivate the proposed criterion, first note that a necessary condition for the context \( \Theta \) to yield a good classifier is that the discriminant \( g(X; \Theta) \) has sufficiently distinct distributions under \( Y = 1 \) and \( Y = 0 \). This can be expressed by requiring that the difference between the expected values of \( g(X; \Theta) \) between the populations, namely

\[
\delta(\Theta) = E[g(X; \Theta) \mid Y = 1, S_n] - E[g(X; \Theta) \mid Y = 0, S_n] \tag{3.6}
\]

be maximized. Notice that this maximization is with respect to \( \Theta \) alone; \( g \) is fixed and chosen \textit{a priori}. In practice, one employs the maximum-likelihood
empirical criterion
\[ \hat{\delta}(\Theta) = \hat{E}[g(X; \Theta) | Y = 1, S_n] - \hat{E}[g(X; \Theta) | Y = 0, S_n], \]  
(3.7)

where
\[ \hat{E}[g(X; \Theta) | Y = c, S_n] = \frac{\sum_{i=1}^n g(X^{(i)}; \Theta)I(Y^{(i)} = c)}{\sum_{i=1}^n I(Y^{(i)} = c)}, \]  
(3.8)

for \( c = 0, 1 \).

In the case of KTSP, the criterion in (3.6) becomes
\[ \delta_{KTSP}((i_1, j_1), \ldots, (i_k, j_k)) = \sum_{r=1}^k \hat{s}_{i_r j_r} \]  
(3.9)

where the pairwise score \( s_{ij} \) for the pair of genes \( (i, j) \) is defined as
\[ s_{ij} = P(X_i < X_j | Y = 1) - P(X_i < X_j | Y = 0). \]  
(3.10)

Notice that if the pair of random variables \( (X_i, X_j) \) has a continuous distribution, so that \( P(X_i = X_j) = 0 \), then we have that \( s_{ij} = -s_{ji} \). In addition, it does not matter in this case whether \( X_i < X_j \) is replaced by \( X_i \leq X_j \) in \( s_{ij} \) in (3.10).

The empirical criterion \( \hat{\delta}_{KTSP}((i_1, j_1), \ldots, (i_k, j_k)) \) (c.f. Eq. 3.7) is obtained by substituting in (3.9) the empirical pairwise scores
\[ \hat{s}_{ij} = \hat{P}(X_i < X_j | Y = 1) - \hat{P}(X_i < X_j | Y = 0). \]  
(3.11)

Here the empirical probabilities are defined by \( \hat{P}(X_i < X_j | Y = c) = \hat{E}[I(X_i < X_j) | Y = c] \), for \( c = 0, 1 \), where the operator \( \hat{E} \) is defined in (3.8).

For TSM, the criterion in (3.6) is given by
\[ \delta_{TSM}(G_k^+, G_k^-) = \]  
\[ E \left[ \text{med}_{j \in G_k^+} R_j - \text{med}_{i \in G_k^-} R_i \bigg| Y = 1 \right] - E \left[ \text{med}_{j \in G_k^+} R_j - \text{med}_{i \in G_k^-} R_i \bigg| Y = 0 \right]. \]  
(3.12)

The following result relates \( \delta_{TSM}(G_k^+, G_k^-) \) to the pairwise scores \( s_{ij} \) defined in (3.10). For notation simplicity, in the following \( m^+ \) and \( m^- \) denote the indices of the genes that achieve the median rank in \( G^+ \) and \( G^- \), respectively.

**Proposition 1.** Assume that the profile vector \( X \) has a probability density, which follows the following (mild) distributional smoothness conditions

(A1) For each \( i \in G_k^-, j \in G_k^+ \), the event \( \{X_i < X_j\} \) is conditionally independent from \( \{m^- = i\} \) and \( \{m^+ = j\} \) given \( Y \).

(A2) The distribution of \( (m^+, m^-) \) is uniform given \( Y \).

Then the criterion (3.12) can be written as
\[ \delta_{TSM}(G_k^+, G_k^-) = \frac{2}{k} \sum_{i \in G_k^- \land j \in G_k^+} s_{ij}, \]  
(3.13)

where \( s_{ij} \) is the pairwise score defined in (3.10).
Proof. See Appendix.

The difference between the two criteria (3.9) for KTSP and (3.13) for TSM for selecting the context is that the former involves scores for \( k \) expression comparisons and the latter involves \( k^2 \) comparisons since each gene \( i \in G_k^- \) is paired with each gene \( j \in G_k^+ \). Moreover, using the estimated solution to maximizing (3.9) (see below) to construct \( G_k^- \) and \( G_k^+ \) by putting the first gene from each pair into one and the second gene from each pair into the other does not work as well in maximizing (3.13) as the algorithms described in the Appendix.

The distributional smoothness conditions in the previous proposition are justified if \( k \) is not too large. We study this in the Appendix. Finally, the empirical criterion \( \hat{\Theta}_{TSM}(G_k^+, G_k^-) \) can be calculated by substituting in (3.13) the empirical pairwise scores \( \hat{s}_{ij} \) defined in (3.11).

### 3.3. Maximization of the Criterion

Maximization of (3.6) or (3.7) works well as long as the size of the context \( |\Theta| \), i.e., the number of context genes, is kept fixed. The reason is that the criterion tends to be monotonically increasing with \( |\Theta| \), which complicates selection. We address this problem by proposing a modified criterion, which is partly inspired by the principle of analysis of variance in classical Statistics. This modified criterion penalizes the addition of more genes to the context by requiring that the variance of \( g(X; \Theta) \) within the populations be minimized. The latter is given by

\[
\hat{\sigma}(\Theta) = \sqrt{\hat{\text{Var}}(g(X; \Theta) \mid Y = 0, S_n) + \hat{\text{Var}}(g(X; \Theta) \mid Y = 1, S_n)},
\]

(3.14)

where \( \hat{\text{Var}} \) is the maximum-likelihood estimator of the variance,

\[
\hat{\text{Var}}(g(X; \Theta) \mid Y = c, S_n) = \frac{\sum_{i=1}^n (g(X^{(i)}; \Theta) - \hat{E}[g(X; \Theta) \mid Y = c, S_n])^2 I(Y^{(i)} = c)}{\sum_{i=1}^n I(Y^{(i)} = c)},
\]

(3.15)

for \( c = 0, 1 \). The modified criterion to be maximized is

\[
\hat{\tau}(\Theta) = \frac{\hat{\delta}(\Theta)}{\hat{\sigma}(\Theta)},
\]

(3.16)

The statistic \( \hat{\tau}(\Theta) \) is reminiscent of the the Welch two-sample t-test statistic of classical hypothesis testing (Casella and Berger [2002]).

Direct maximization of (3.7) or (3.16) is in general a hard computational problem for the numbers of genes typically encountered in expression data. We propose instead a greedy procedure. Assuming that a pre-defined range of values \( \Omega \) for the context size \( |\Theta| \) is given, the procedure is:
(1) For each value of $k \in \Omega$, an optimal context $\Theta_k^*$ is chosen that maximizes (3.7) among all contexts $\Theta_k$ containing $k$ genes:
\[
\Theta_k^* = \arg \max_{|\Theta| = k} \hat{\delta}(\Theta).
\] (3.17)

(2) An optimal value $k^*$ is chosen that maximizes (3.16) among all contexts $\{\Theta_k^* | k \in \Omega\}$ obtained in the previous step:
\[
k^* = \arg \max_{k \in \Omega} \hat{\tau}(\Theta_k^*).
\] (3.18)

For KTSP, the maximization in step (1) of the previous context selection procedure becomes
\[
\{(i_1^*, j_1^*), \ldots, (i_k^*, j_k^*)\} = \arg \max \max_{(i_1, j_1), \ldots, (i_k, j_k)} \delta_{KTSP}((i_1, j_1), \ldots, (i_k, j_k))
\]
\[
= \arg \max_{(i_1, j_1), \ldots, (i_k, j_k)} \sum_{r=1}^{k} \hat{s}_{i_r; j_r}.
\] (3.19)

We propose a greedy approach to this maximization problem: initialize the list with the top scoring pair of genes, then keep adding pairs to the list whose genes have not appeared so far (ties are broken by the secondary score proposed in Xu et al. [2005]). This process is repeated until $k$ pairs are chosen. This corresponds essentially to the same method that was proposed, for fixed $k$, in the original paper on KTSP (Tan et al. [2005]). This shows that the previously-proposed heuristic has a justification in terms of maximizing the separation between the rank discriminant (3.2) across the classes.

To obtain the optimal value $k^*$, one applies step (2) of the context selection procedure, with a range of values $k \in \Omega = \{3, 5, \ldots, K\}$, for odd $K$ ($k = 1$ can be added if 1-TSP is considered). Note that here
\[
\hat{\sigma}_{KTSP}(\Theta) = \sqrt{\text{Var} \left( \sum_{r=1}^{k} [I(X_{i_r} < X_{j_r})] | Y = 0 \right) + \text{Var} \left( \sum_{r=1}^{k} [I(X_{i_r} < X_{j_r})] | Y = 1 \right)}.
\] (3.20)

Therefore, the optimal value of $k$ is selected by
\[
k^* = \arg \max_{k=3,5,\ldots,K} \hat{\tau}_{KTSP}((i_1^*, j_1^*), \ldots, (i_k^*, j_k^*))
\] (3.21)

where
\[
\hat{\tau}_{KTSP}((i_1^*, j_1^*), \ldots, (i_k^*, j_k^*)) = \frac{\hat{\delta}_{KTSP}((i_1^*, j_1^*), \ldots, (i_k^*, j_k^*))}{\hat{\sigma}_{KTSP}((i_1^*, j_1^*), \ldots, (i_k^*, j_k^*))}
\]
\[
= \frac{\sum_{r=1}^{k} \hat{s}_{i_r; j_r}}{\sqrt{\text{Var} \left( \sum_{r=1}^{k} [I(X_{i_r} < X_{j_r})] | Y = 0 \right) + \text{Var} \left( \sum_{r=1}^{k} [I(X_{i_r} < X_{j_r})] | Y = 1 \right)}}.
\] (3.22)

Finally, the optimal context is then given by $\Theta^* = \{(i_1^*, j_1^*), \ldots, (i_k^*, j_k^*)\}$. 
For TSM, the maximization in step (1) of the context selection procedure can be written as

\[
(G_k^+, G_k^-) = \arg \max_{(G_k^+, G_k^-)} \hat{\delta}_{\text{TSM}}(G_k^+, G_k^-)
\]

\[
= \arg \max_{(G_k^+, G_k^-)} \sum_{i \in G_k^-, j \in G_k^+} \hat{\delta}_{ij},
\]

Equation (3.23)

Finding the global maximum in (3.23) is not feasible in general. We consider a sub-optimal strategy for accomplishing this task: sequentially construct the context by adding two genes at a time. Start by selecting the TSP pair \(i, j\) and setting \(G_k^+ = \{i\}\) and \(G_k^- = \{j\}\). Then select the pair of genes \(i', j'\) distinct from \(i, j\) such that the sum of scores is maximized by \(G_{k+1}^+ = \{i, i'\}\) and \(G_{k+1}^- = \{j, j'\}\), i.e., \(\hat{\delta}_{\text{TSM}}(G_k^+, G_k^-)\) is maximized over all sets \(G_k^+, G_k^-\) of size two, assuming \(i \in G_k^-\) and \(j \in G_k^+\). This involves computing three new scores. Proceed in this way until \(k\) pairs have been selected.

To obtain the optimal value \(k^*\), one applies step (2) of the context selection procedure, with a range of values \(k \in \Omega = \{3, 5, \ldots, K\}\), for odd \(K\) (the choice of \(\Omega\) is dictated by the facts that \(k = 1\) reduces to 1-TSP, whereas Proposition 1 does not hold for even \(k\)):

\[
k^* = \arg \max_{k=3,5,\ldots,K} \hat{\tau}_{\text{TSM}}(G_k^+, G_k^-)
\]

where

\[
\hat{\tau}_{\text{TSM}}(G_k^+, G_k^-) = \frac{\hat{\delta}_{\text{TSM}}(G_k^+, G_k^-)}{\hat{\sigma}_{\text{TSM}}(G_k^+, G_k^-)}
\]

\[
= \sqrt{\frac{\hat{E} \left[ \text{med}_{j \in G_k^+} R_j - \text{med}_{i \in G_k^-} R_i \mid Y = 1 \right] - \hat{E} \left[ \text{med}_{j \in G_k^+} R_j - \text{med}_{i \in G_k^-} R_i \mid Y = 0 \right]}{\hat{\text{Var}} \left[ \text{med}_{j \in G_k^+} R_j - \text{med}_{i \in G_k^-} R_i \mid Y = 0 \right] + \hat{\text{Var}} \left[ \text{med}_{j \in G_k^+} R_j - \text{med}_{i \in G_k^-} R_i \mid Y = 1 \right]}}.
\]

Equation (3.25)

Notice that \(\hat{\tau}_{\text{TSM}}\) is defined directly by replacing (3.4) into (3.7) and (3.14), and then using (3.16). In particular, it does not use the approximation in (3.13). Finally, the optimal context is given by \(\Theta^* = (G_{k^*}^+, G_{k^*}^-)\).

For both KTSP and TSM classifiers, the step-wise process to perform the maximization of the criterion, c.f. Eqs. (3.19) and (3.23), does not need to be restarted as \(k\) increases, since the sub-optimal contexts are nested (by contrast, the method in Tan et al. [2005] employed cross-validation to choose \(k^*\)). The detailed context selection procedure for KTSP and TSM classifiers is given in pseudo-code in the Appendix.
3.4. Error Rates

In this section, we discuss the choice of the threshold \( t \) used in (3.1). The sensitivity is defined as \( P(f(X) = 1 \mid Y = 1) \) and the specificity is defined as \( P(f(X) = 0 \mid Y = 0) \). We are interested in controlling both, but trade-offs are inevitable. The choice of which phenotype to designate as 1 is application-dependent; often sensitivity is relative to the more malignant one and this is the way we have assigned labels to the phenotypes. A given application may call for emphasizing sensitivity at the expense of specificity or vice-versa. For example, in detecting BRCA1 mutations, or with aggressive diseases such as pancreatic cancer, high sensitivity is important, whereas for more common and less aggressive cancers, such as prostate, it may be preferable to limit the number of false alarms and achieve high specificity. In principle, selecting the appropriate threshold \( t \) in (3.1) allows one to achieve a desired tradeoff. (A disadvantage of TSP is the lack of a discriminant, and thus a procedure to adjust sensitivity and specificity.) It should be noted, however, that in practice estimating the threshold on the training data can be difficult; moreover, introducing a non-zero threshold makes the decision rule somewhat more difficult to interpret. As an example, Figure 2 displays the ROC curve of the TSM classifier for the BRCA1 and Prostate 4 studies, together with thresholds achieving hypothetically desired scenarios.

![ROC curves for TSM and two datasets](image)

**Fig 2.** ROC curves for TSM and two datasets. Left: BRCA1. With the indicated threshold, we can achieve the sensitivity around 0.9 at the expense of specificity around 0.6. Right Prostate 4: The given threshold reaches 0.88 specificity at the expense of sensitivity around 0.55.
A summary of the rank-based discriminants developed in the preceding sections is given in Table 2. We learned each one for each of the datasets listed in Table 1. Among an abundance of proposed methods for high-dimensional data classification (e.g., Bradley and Mangasarian [1998], Zhang et al. [2006], Marron et al. [2007]), we chose two of the most effective and popular choices for predicting phenotypes from expression data: PAM (Tibshirani et al. [2002]), which is a form of LDA, and SVM-RFE (Guyon et al. [2002]), which is a form of linear SVM.

Generalization errors are estimated with cross-validation, specifically averaging the results of ten repetitions of ten-fold CV, as recommended in Braga-Neto and Dougherty [2004] and Hastie et al. [2001]. Despite the inaccuracy of small-sample cross-validation estimates (Braga-Neto and Dougherty [2004]), this suffices to obtain the broad perspective on relative performance across many different datasets.

Estimated classification rates are presented in Figure 3 and 4. The protocols for training (including parameter selection) are given below. To reduce computation, we filter the whole gene pool without using the class labels before selecting the context for rank discriminants (TSP, KTSP and TSM). Although a variety of filtering methods exist in the literature, such as PAM (Tibshirani et al. [2002]), SIS (Fan and Lv [2008]), Dantzig selector (Candes and Tao [2007]) and the Wilcoxon-Rank test (Wilcoxon [1945]), we simply use an average signal filter: select the 4000 genes with highest mean rank (across both classes). In particular, there is no effort to detect “differentially expressed” genes. In this way
we minimize the influence of the filtering method in assessing the performance of rank discriminants.

- **TSP**: The single pair which maximizing $s_{ij}$ over all pairs in the 4000 filtered genes, breaking scoring ties if necessary with the secondary score proposed in Xu et al. [2005].
- **KTSP**: The $k$ disjoint pairs maximizing $s_{ij}$ over all pairs in the 4000 filtered genes with the same tie-breaking method. The number of pairs $k$ is determined via Algorithm 1, within the range $k = 3, 5, \ldots, 9$, avoiding ties in voting. Notice that $k = 1$ is excluded so that KTSP cannot reduce to TSP. We tried also $k = 3, 5, \ldots, 49$ and the cross-validated accuracies changed insignificantly.
- **TSM**: The context is chosen from the top 4000 genes by the greedy selection procedure described in Algorithm 2. The size of the two sets for computing the median rank is selected in the range $k = 3, 5, 7, 9$ (providing a unique median and thereby rendering Proposition 1 applicable). We also tried $k = 3, 5, \ldots, 49$ and again the change in the cross-validated accuracies were insignificant.
- **SVM-RFE**: We learned two linear SVMs using SVM-RFE: one with ten genes and one with a hundred genes. No filtering was applied, since SVM-RFE itself does that. Since we found that the choice of the slack variable barely changes the results, we fix $C = 0.1$. (In fact, the data are linearly separable in nearly all loops.) Only the results for SVM-RFE with a hundred genes are shown since it was almost 3% better than with ten genes.
- **PAM**: We use the automatic filtering mechanism provided by Tibshirani [2011]. The prior class likelihoods were set to 0.5 and all other parameters were set to default values. The most important parameter is the threshold; the automatic one chosen by the program results in relatively lower accuracy than the other methods (84.00%) on average. Fixing the threshold and choosing the best one over all datasets only increases the accuracy by one percent. Instead, for each dataset and each threshold, we estimated the cross-validated accuracy for PAM and report the accuracy of the best threshold for that dataset.

Figure 3 and 4, and Table 3 show the performance estimates of the classifiers across 21 datasets in box plot format. The averages are: TSP (85.59%), KTSP (90.07%), TSM (88.97%), SVM-RFE (89.92%) and PAM (88.19%). The differences in the averages among methods do not appear substantial, with the possible exception of TSP, which lags behind the others.

There are however clearly significant variations in performance within individual datasets. In order to examine these variations at a finer scale, possibly revealing trends to support practical recommendations, recall that for each dataset and each method, we did ten repetitions of ten-fold cross-validation, resulting in one hundred trained classifiers and estimated rates (on the left-out subsets), which were averaged to provide a single cross-validated classification rate. The notch-boxes for each dataset and method are plotted in figure 3 and figure 4. As is commonly done, any two methods will be declared to be “tied” on
a given dataset if the notches overlap; otherwise, i.e., if the notches are disjoint, the “winner” is taken to be the one with the larger median.

First, as concerns the three RIC classifiers, and using the notch test, KTSP slightly out-performs TSM, which in turn out-performs TSP. More specifically, KTSP has accuracy superior to both others on ten datasets. In terms of TSP vs. TSM, KTSP outperforms on three datasets, vice-versa on one dataset and they tie on all others. Moreover, TSM outperforms TSP on nine datasets and vice-versa on two datasets. As a result, if accuracy is the dominant concern, we recommend KTSP among the RIC classifiers, whereas if simplicity, transparancey and links to biological mechanism are important, one might prefer TSP. Comparisons with non-RIC methods (see below) we will then be based on KTSP, although substituting TSM does not lead to appreciably different conclusions.

Second, as concerns PAM vs. SVM, SVM performs better on six datasets and PAM on three datasets. Hence, in the remainder of this section we will compare KTSP with SVM. We emphasize that the comparison between PAM and SVM is on our particular datasets, using our particular measures of performance, namely cross-validation to estimate accuracy and the notch test for pairwise comparisons, and we are not by any means recommending SVM over PAM in general.

Third, in comparing KTSP and SVM, whereas their overall performance statistics are almost identical, trends do emerge based on sample size, which is obviously an important parameter and especially useful here because it varies considerably among our datasets (Table 1). To avoid fine-tuning, we only consider a coarse and somewhat arbitrary quantization into three categories: “small,”

| Dataset | TSP | TSM | KTSP | SVM | PAM |
|---------|-----|-----|------|-----|-----|
| Colon   | 85/88 | 86/88 | 87/86 | 87/73 | 84/81 |
| BRCA1   | 71/75 | 90/75 | 88/77 | 68/88 | 39/82 |
| CNS     | 41/79 | 81/88 | 67/93 | 52/86 | 77/79 |
| DLBCL   | 98/97 | 96/95 | 96/88 | 97/91 | 72/100 |
| Lung    | 92/97 | 97/99 | 94/100 | 95/100 | 97/100 |
| Marfan  | 82/93 | 89/90 | 88/96 | 99/93 | 88/87 |
| Crohn’s | 89/90 | 92/91 | 92/96 | 100/100 | 93/98 |
| Sarcoma | 83/78 | 88/89 | 93/91 | 97/94 | 93/100 |
| Squamous| 89/88 | 88/85 | 99/92 | 94/95 | 94/95 |
| GCM     | 81/73 | 88/77 | 90/75 | 94/80 | 95/94 |
| Leukemia 1 | 90/85 | 97/94 | 97/93 | 98/97 | 95/89 |
| Leukemia 2 | 96/96 | 100/93 | 100/96 | 100/96 | 73/88 |
| Leukemia 3 | 98/98 | 97/99 | 97/98 | 100/100 | 96/99 |
| Leukemia 4 | 92/94 | 95/98 | 96/97 | 99/97 | 77/92 |
| Prostate 1 | 95/93 | 89/96 | 90/95 | 91/95 | 89/91 |
| Prostate 2 | 68/68 | 76/79 | 76/83 | 68/79 | 77/74 |
| Prostate 3 | 97/79 | 99/90 | 99/83 | 99/100 | 98/100 |
| Prostate 4 | 77/61 | 87/70 | 86/79 | 92/62 | 66/85 |
| Prostate 5 | 97/99 | 97/98 | 95/99 | 100/99 | 99/100 |
| Breast 1 | 82/90 | 82/91 | 85/91 | 77/88 | 95/98 |
| Breast 2 | 83/82 | 73/89 | 75/87 | 71/86 | 86/88 |

Table 3
Sensitivity/specificity for different classification methods. Overall accuracy is calculated as the average of sensitivity and specificity.
“medium” and “large” datasets, defined, respectively, by fewer than 100 (total) samples (twelve datasets), 100-200 samples (five datasets) and more than 200 samples (four datasets). On small datasets, KTSF outperforms SVM on four datasets and never vice-versa; for medium datasets each outperforms the other on one of the five datasets; and SVM outperforms KTSF on three out of four large datasets and never vice versa.

Another criterion is sparsity: the number of genes used by TSP is always two and by SVM-RFE is always one hundred. Averaged across all datasets and loops of cross-validation, KTSF uses 12.5 genes, TSM uses 10.16 genes, and PAM uses 5771 genes.

Finally, we performed an experiment to roughly gauge the variability in selecting the genes in the support of the various classifiers. Taking advantage of the fact that we train 100 different classifiers for each method and dataset, each time with approximately the same number of examples, we define a “consistency” measure for a pair of classifiers as the average support overlap over all distinct pairs of runs. That is, for any given dataset and method, and any two loops of cross validation, let $S_1$ and $S_2$ be the supports (set of selected genes) and define the overlap as $\frac{|S_1 \cap S_2|}{|S_1 \cup S_2|}$. This fraction is then averaged over all 100(99)/2 pairs of loops, and obviously ranges from zero (no consistency) to one (consistency in all loops). Whereas in 16 of the 21 datasets KTSF had a higher consistency score than SVM, the more important point is that in both cases the scores are low in absolute terms, which coheres with other observations about the enormous variations in learned genes signatures.

5. Discussion and Conclusions

What might be a “mechanistic interpretation” of the TSP classifier, where the context consists of only two genes? In Price et al. [2007], a reversal between the two genes Prune2 and Obscurin is shown to be an accurate test for separating GIST and LMS. Providing an explanation, an hypothesized mechanism, is not straightforward, although it has been recently shown that both modulate RhoA activity (which controls many signaling events): a splice variant of Prune2 is reported to decrease RhoA activity when over-expressed and Obscurin contains a Rho-GEF binding domain which helps to activate RhoA (Funk [2012]).

Generically, one of the most elementary regulatory motifs is simply $A$ inhibits $B$ (denoted $A \dashv B$). For example, $A$ may be constitutively “on” and $B$ constitutively “off” after development. Perhaps $A$ is a transcription factor or involved in methylation of $B$. In the normal phenotype we see $A$ expressed but perhaps $A$ becomes inactivated in the cancer phenotype, resulting in the expression of $B$, and hence an expression reversal from normal to cancer. Still more generally, a variety of regulatory feedback loops have been identified in mammals. For instance, an example of a bi-stable loop is shown below.
Due to the activation and suppression patterns depicted in Figure 5, we might expect $P(X_{A_1} < X_{A_2} | Y = 0) \gg P(X_{A_1} < X_{A_2} | Y = 1)$ and $P(X_{B_1} < X_{B_2} | Y = 0) \ll P(X_{B_1} < X_{B_2} | Y = 1)$. Thus there are two expression reversals, one between the two miRNAs and one, in the opposite direction, between the two mRNAs. Given both miRNA and mRNA data, we might then build a classifier based on the these two switches. For example, the rank discriminant might simply be $2TSP$, the number of reversals observed. It is in this sense that we have argued that expression comparisons may provide an elementary building block for a connection between rank-based decision rules and potential mechanism.

We have reported extensive experiments with classifiers based on expression comparisons with different diseases and microarray platforms and compared the results with other methods which usually use significantly more genes. No one classifier, whether within the rank-based collection or between these and other methods such as $SVM$ and $PAM$, is uniformly dominant. The most appropriate one to use is likely to be problem-dependent. Moreover, until much larger datasets become available, it will be difficult to obtain highly accurate estimates of generalization errors. What does seem apparent is that our results support the conclusions reached in earlier studies (Dudoit et al. [2002], Braga-Neto [2007], Wang [2012], Simon et al. [2003]) that simple classifiers are usually competitive with more complex ones with microarray data and limited samples. This has important consequences for future developments in functional genomics since one key thrust of “personalized medicine” is an attempt to learn appropriate treatments for disease subtypes, which means sample sizes will not necessarily get larger and might even get smaller. Moreover, as attention turns increasingly towards treatment, potentially mechanistic characterizations of statistical decisions will become of paramount importance for translational medicine.

Appendix
Testing the Assumptions (A1), (A2). Recall that the empirical score $\delta_{TSM}$ is maximized by maximizing the expression in (3.13) from Proposition 1, provided that two assumptions (A1) and (A2) are satisfied. The first assumption was investigated by with Fisher’s exact test to check if the events $\{X_i < X_j\}$ and $\{m_+ = i\}$ are conditionally independent given $Y$. Because of symmetry, checking the assumption for the event $\{m_- = j\}$ is unnecessary. To check the conditional independence assumption, we randomly chose a subset of genes $G^-$ with random odd size. For each gene $i \in G^-$, we chose a random gene $j$ and tested the hypothesis $\{X_i < X_j\}$ and $\{m_- = i\}$ are independent given $Y$: we formed the contingency table of the two random variables $I(X_i < X_j)$ and $I(m_- = i)$, given the data from each class separately. We computed the $p$-value for Fisher’s exact test for ten thousand random choices of $G^-$ and $j$. The independence hypothesis was not rejected in nearly all cases. In fact, in all the datasets except Prostate1, we observed $p < 0.05$ in fewer than $3\%$ of the trials. (For Prostate1, the rate of rejection was five percent.)

The second assumption behind the criterion for choosing the context is that the distribution of the indices of the medians is roughly uniform. One example is illustrated in Table 4 for the full Sarcoma dataset using the selection procedure in Algorithm 2 with the score in (3.11). The data are roughly consistent with samples from the uniform distribution. ($p \approx 1$ using $\chi^2$-test) Over our twenty one datasets, the test of uniformity typically yields $p$-values higher than $0.1$, although $p < 0.05$ was observed in six of the datasets. Still, even in those cases, we do not observe extreme concentration on a few pairs of indices.

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|}
\hline
& $X_8$ & $X_7$ & $X_6$ & $X_5$ \\
\hline
$X_1$ & .03 & .01 & .08 & .04 \\
$X_2$ & .03 & .00 & .06 & .05 \\
$X_3$ & .01 & .04 & .06 & .06 \\
$X_4$ & .04 & .06 & .06 & .04 \\
$X_5$ & .03 & .08 & .06 & .07 \\
\hline
\end{tabular}
\caption{Median distribution on Sarcoma. The genes in $G_1$ (resp., $G_2$) are labeled 1,...,5 (resp., 6,...,10) for the optimal context. Shown is the percentage of samples for which each pair assumes the median.}
\end{table}

Proof of Proposition 1. First notice that, for any $j \in G^+_k \cup G^-_k$, we have

$$R_j = \sum_{i \in G^+_k \cup G^-_k} I(X_j \geq X_i) = \sum_{i \in G^+_k} I(X_j \geq X_i) + \sum_{i \in G^-_k} I(X_j \geq X_i).$$

Hence (assuming odd $k$),

$$\text{med}_{i \in G^+_k} R_i = \sum_{i \in G^+_k} I(X_{m+} \geq X_i) + \sum_{i \in G^-_k} I(X_{m+} \geq X_i) = \frac{k + 1}{2} + \sum_{i \in G^-_k} I(X_{m+} \geq X_i)$$

and
\[
\text{med } R_i = \sum_{i \in G_k^+} I(X_{m}^{-} \geq X_i) + \sum_{i \in G_k^-} I(X_{m}^{+} \geq X_i)
\]
\[
= \sum_{i \in G_k^+} I(X_{m}^{-} \geq X_i) + \frac{k+1}{2}.
\]

Therefore,
\[
E \left[ \text{med } R_i - \text{med } R_i \bigg| Y = c \right] = \sum_{i \in G_k^-} P(X_{m}^{+} \geq X_i \mid Y = c) - \sum_{i \in G_k^+} P(X_{m}^{-} \geq X_i \mid Y = c),
\]
for \(c = 0, 1\), so that the criterion (3.12) can be written as
\[
\delta_{TSM}(G_k^+ \mid G_k^-) = \sum_{i \in G_k^-} (P(X_{m}^{+} \geq X_i \mid Y = 1) - P(X_{m}^{+} \geq X_i \mid Y = 0))
\]
\[
- \sum_{i \in G_k^+} (P(X_{m}^{-} \geq X_i \mid Y = 1) - P(X_{m}^{-} \geq X_i \mid Y = 0)).
\]

But the smoothness conditions (A1) and (A2) allow us to write
\[
P(X_{m}^{+} \geq X_i \mid Y = c) = \sum_{j \in G_k^+} P(X_j \geq X_i \mid Y = c, m^+ = j)P(m^+ = j \mid Y = 1)
\]
\[
= \frac{1}{k} \sum_{j \in G_k^+} P(X_j \geq X_i \mid Y = c)
\]

and
\[
P(X_{m}^{-} \geq X_i \mid Y = c) = \sum_{j \in G_k^-} P(X_j \geq X_i \mid Y = c, m^- = j)P(m^- = j \mid Y = 1)
\]
\[
= \frac{1}{k} \sum_{j \in G_k^-} P(X_j \geq X_i \mid Y = c),
\]
Algorithm 1 KTSP Context Selection Algorithm. The context is initialized with the TSP and the best pair of genes not in the current context is added at each step. The maximum number of pairs of genes is $K$ and the output is the selected context $\Theta^* \leftarrow \{ (i_1^*, j_1^*), \ldots, (i_k^*, j_k^*) \}$.

1. Calculate $\hat{s}_{ij} = \hat{P}(X_i < X_j \mid Y = 1) - \hat{P}(X_i < X_j \mid Y = 0)$ for all $i, j$
2. For $k = 2, \ldots, K$
   a. Let $(i_k^*, j_k^*) = \arg \max_{i,j \notin \{(i_1^*, j_1^*), \ldots, (i_{k-1}^*, j_{k-1}^*)\}} \hat{s}_{ij}$ (Add the best available pair of genes.)
   b. Let $t^* = \frac{\hat{\tau}_{\text{KTSP}}((i_1^*, j_1^*), \ldots, (i_k^*, j_k^*))}{t}$ (Definition in (3.22))
   c. If $t > t^*$ and $k \in \{3, 5, \ldots\}$ then $k^* \leftarrow k$
3. $\Theta^* \leftarrow \{ (i_1^*, j_1^*), \ldots, (i_k^*, j_k^*) \}$ (Optimal context)

for $c = 0, 1$. Substituting these back into (5.5), we obtain

$$\delta_{\text{TSM}}(G_k^+, G_k^-) = \frac{1}{k} \sum_{i \in G_k^-} \sum_{j \in G_k^+} (P(X_j \geq X_i \mid Y = 1) - P(X_j \geq X_i \mid Y = 0))$$

$$- \frac{1}{k} \sum_{j \in G_k^-} \sum_{i \in G_k^+} (P(X_j \geq X_i \mid Y = 1) - P(X_j \geq X_i \mid Y = 0))$$

$$= \frac{1}{k} \sum_{i \in G_k^-} \sum_{j \in G_k^+} (s_{ij} - s_{ji})$$

$$= \frac{2}{k} \sum_{i \in G_k^-} \sum_{j \in G_k^+} s_{ij},$$

where we used the fact that $s_{ji} = -s_{ij}$. □

Pseudo-code for the KTSP and TSM classifiers. Please see the pseudo-code in Algorithm 1 and Algorithm 2.

References

U. Alon, N. Barkai, D. Notterman, and et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. PNAS, 96(12), 1999.

R. B. Altman, C. A. M. Ho K. Kroemer, and et al. Pharmacogenomics: will the promise be fulfilled. Nature Reviews, 12:69–73, 2011.

T. Anderson, I. Tchernyshyov, R. Diez, and et al. Discovering robust protein biomarkers for disease from relative expression reversals in 2-D DIGE data. Proteomics, 7(8), 2007.
Algorithm 2: TSM Context Selection Algorithm: The context is initialized by splitting the TSP and the best pair of genes not in the current context is added at each step. The maximum number of genes in $G^+_k$ and $G^-_k$ is $K$ and the output is the selected context $\Theta^* \leftarrow (G^+_k, G^-_k)$.

Calculate $\bar{s}_{ij} = \hat{P}(X_i < X_j \mid Y = 1) - \hat{P}(X_i < X_j \mid Y = 0)$ for all $i, j$

$(i^*, j^*) = \arg\max_{i,j} \bar{s}_{ij}$

$G^+ = \{i^*\}$ and $G^- = \{j^*\}$ \{Split TSP into $G^+_1$ and $G^-_1$\}

$k^* \leftarrow 1, t^* \leftarrow -1$ \{Initialize with TSP\}

for $k = 2$ to $K$ do
  $(i^*, j^*) = \arg\max_{(i,j) \notin G^+_1 \cup G^-_1} \sum_{u \in G^+_1 \cup \{i\}} \sum_{w \in G^-_1 \cup \{j\}} \bar{s}_{uw}$
  $G^-_{k^*} \leftarrow G^-_{k^*-1} \cup \{i^*\}$
  $G^+_{k^*} \leftarrow G^+_{k^*-1} \cup \{j^*\}$ \{Add the best available pair of genes.\}
  $t \leftarrow \tau_{TSM}(G^+_k, G^-_k)$ \{$\tau_{TSM}$ defined in (3.25)\}
  if $t > t^*$ and $k \in \{3, 5, \ldots\}$ then
    $t^* \leftarrow t, k^* \leftarrow k$
  end if
end for

$\Theta^* \leftarrow (G^+_k, G^-_k)$ \{Optimal context.\}
and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. *Cancer Research*, (71):5635–45, 2011.

M. Burczynski, R. Peterson, N. Twine, and et al. Molecular classification of Crohn’s disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. *The Journal of Molecular Diagnostic*, 8 (1):51–61, 2006.

E. Candes and T. Tao. The dantzig selector: statistical estimation when p is much larger than n. *Annals of Statistics*, 35(6):2313–2351, 2007.

G. Casella and R. Berger. *Statistical Inference*. Duxbury, Pacific Grove, CA, 2nd edition, 2002.

M. Dettling and P. Bühlmann. Boosting for tumor classification with gene expression data. *Bioinformatics*, 19(1061-1069), 2003.

S. Dudoit, J. Fridlyand, and T. P. Speed. Comparison of discrimination methods for the classification of tumors using gene expression data. *Journal of the American Statistical Association*, 97(457):77–87, 2002.

L. Edelman, G. Toia, D. Geman, and et al. Two-transcript gene expression classifiers in the diagnosis and prognosis of human diseases. *BMC Genomics*, 10(583), 2009.

E. Enerly, I. Steinfeld, K. Kleivi, S.-K. Leivonen, M. R. Russnes, J. A. Ranieberg, H. Johnsen, R. Navon, E. Rdland, R. Mkel, B. Naume, M. Perl, O. Kallioniemri, V. N. Kristensen, Z. Yakhini, and M. Anne-Lise Bresnen-Dale. mirna-mrna integrated analysis reveals roles for mirnas in primary breast tumors. *PLOS ONE*, 6(2), 2011.

J. P. Evans, E. M. Meslin, T. M. Marteau, and T. Caulfield. Deflating the genomic bubble. *Science*, 331:861–862, 2011.

J. Fan and Y. Fan. High dimensional classification using features annealed independence rules. *Annals of statistics*, 36(6):2605, 2008.

J. Fan and J. Lv. Sure independence screening for ultrahigh dimensional feature space. *Royal Statistical Society Journal of the Royal Statistical Society Series B*, 70, 2008.

C. Funk. Personal Communication, 2012. Institute for Systems Biology, Seattle, WA.

D. Geman, C. d’Avignon, D. Naiman, and et al. Gene expression comparisons for class prediction in cancer studies. In *Proceedings 36th Symposium on the Interface: Computing Science and Statistics*, 2004.

D. Geman, B. Afsari, and D. N. A.C. Tan. Microarray classification from several two-gene expression comparisons. 2008. (Winner, ICMLA Microarray Classification Algorithm Competition).

T. R. Golub, D. K. Slonim, P. Tamayo, and et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. *Science*, 286(5439):531–537, 1999.

G. J. Gordon, R. V. Jensen, L.-L. Hsiao, S. R. Gullans, J. E. Blumenstock, S. Ramaswamy, W. G. Richards, D. J. Sugarbaker, and R. Bueno. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. *Cancer Research*, (62):4963–4967, 2002.
Y. Guo, T. Hastie, and R. Tibshirani. Regularized discriminant analysis and its application in microarrays. *Biostatistics*, 1(1):1–18, 2005.

Y. Guo, T. Hastie, and R. Tibshirani. Regularized linear discriminant analysis and its application in microarrays. *Biostatistics*, 8:86–100, 2007.

I. Guyon, J. Weston, S. Barnhill, and V. Vapnik. Gene selection for cancer classification using support vector machines. *Machine Learning*, 46(1-3):389–422, 2002.

T. Hastie, R. Tibshirani, and J. Friedman. *The Elements of Statistical Learning: Data Mining, Inference, and Prediction*. Springer, 2001.

S. Jones, X. Zhang, D. W. Parsons, and et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science*, 321(5897):1801–1806, 2008.

J. Khan, J. S. Wei, M. Ringn, and et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. *Nature Medicine*, 7(673-679), 2001.

A. Kohlmann, T. K. Tij, L. Rassenti, J. Downing, and et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the microarray innovations in leukemia study prephase. *Br J Haematol*, 2008. GEO Accession: GSE13159.

M. A. Kuriakose, W. T. Chen, and et al. Selection and validation of differentially expressed genes in head and neck cancer. *Cellular and Molecular Life Sciences*, 61:13721383, 2004.

E. Lee, H. Chuang, J. Kim, and et al. Inferring pathway activity toward precise disease classification. *PLOS Computational Biology*, 4, 2008.

X. Lin, B. Afsari, L. Marchionini, and et al. The ordering of expression among a few genes can provide simple cancer biomarkers and signal brca1 mutations. *BMC Bioinformatics*, 10(256), 2009.

X.-J. Ma, Z. Wang, P. D. Ryan, and et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. *Cancer Cell*, 5(6), 2004.

J. S. Marron, M. Todd, , and J. Ahn. Distance weighted discrimination. *JASA*, 102(480):1267–1271, 2007.

E. Marshall. Waiting for the revolution. *Science*, 331:526–529, 2011.

K. Mills, A. Kohlmann, P. Williams, L. Wieczorek, and et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of aml transformation of myelodysplastic syndrome. *Blood*, 2009.

S. Peng, Q. Xu, X. Ling, and et al. Molecular classification of cancer types from microarray data using the combination of genetic algorithms and support vector machines. *FEBS Letters*, (555):358–362, 2003.

C. Pomeroy, P. Tamayo, M. Gaasenbeek, and et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. *Nature*, 415 (6870):436–442, 2002.

N. Price, J. Trent, A. El-Naggar, and et al. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leimyosarcomas. *PNAS*, 43(102), 2007.
Y. Qu, B. Adam, Y. Yasui, and et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. *Clinical Chemistry*, 48:1835–1843, 2002.

S. Ramaswamy, P. Tamayo, R. Rifkin, and et al. Multiclass cancer diagnosis using tumor gene expression signatures. *PNAS*, 98(26):15149–15154, 2001.

M. Raponi, J. E. Lancet, H. Fan, and et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. *Blood*, 111(5):2589–2596, 2008.

M. Shipp, K. Ross, P. Tamayo, and et al. Diffuse large b-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. *Nat Med*, 8:68–74, 2002.

R. Simon, M. D. Radmacher, K. Dobbin, and L. M. McShane. Pitfalls in the use of dna microarray data for diagnostic and prognostic classification. *Journal of the National Cancer Institute*, 95(1):14–18, 2003.

D. Singh, P. Febbo, K. Ross, and et al. Gene expression correlates of clinical prostate cancer behavior. *Cancer Cell*, 1(2):203–209, 2002.

R. Stuart, W. Wachsman, C. Berry, and et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. *PNAS*, 101(2):615–620, 2004.

A. C. Tan, D. Q. Naiman, L. Xu, and et al. Simple decision rules for classifying human cancers from gene expression profiles. *Bioinformatics*, 21(20):3896–3904, 2005.

R. K. Thomas, A. C. Baker, R. M. DeBiasi, and et al. High-throughput oncogene mutation profiling in human cancer. *Nature Genetics*, 39:347–351, 2007.

R. Tibshirani. Pam r package. http://www-stat.stanford.edu/~tibs/PAM/Rdist/index.html, January 2011.

R. Tibshirani, T. Hastie, B. Narasimhan, and G. Chu. Diagnosis of multiple cancer types by shrunken centroids of gene expression. *PNAS*, 99(10):6567–6572, 2002.

X. Wang. Robust two-gene classifiers for cancer prediction. *Genomics*, 99(2):90–95, 2012.

R. R. Weichselbaum, H. Ishwaranc, T. Yoona, and et al. An interferon-related gene signature for dna damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. *PNAS*, 105(47):1849018495, 2008.

J. Welsh, L. Sapinoso, A. Su, and et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. *Cancer Res*, 61(16):5974–5978, 2001.

F. Wilcoxon. Individual comparisons by ranking methods. *Biometrics*, pages 80–83, 1945.

R. Winslow, N. Trayanova, D. Geman, and M. Miller. The emerging discipline of computational medicine. *Science Translational Medicine*, 4(158):158rv11, 2012.

L. Xu, A. C. Tan, D. Q. Naiman, and et al. Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. *BMC Bioinformatics*, 21(20):39053911, 2005.
L. Xu, D. Geman, and R. L. Winslow. Large-scale integration of cancer microarray data identifies a robust common cancer signature. *BMC Bioinformatics*, 8(275), 2007.

Z. Yao, J. Jaeger, W. L. Ruzzo, and et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. *Journal of Clinical Oncology*, 22(14):2790–2799, 2004.

Z. Yao, J. Jaeger, W. Ruzzo, and et al. A marfan syndrome gene expression phenotype in cultured skin fibroblasts. *BMC Genomics*, 8(319), 2007.

C. Yeang, S. Ramaswamy, P. Tamayo, and et al. Molecular classification of multiple tumor types. *Bioinformatics*, 17(316-322), 2001.

H. Zhang, C. Y. Yu, and B. Singer. Cell and tumor classification using. *PNAS*, 100:4168–4172, 2003.

H. H. Zhang, J. Ahn, X. Lin, and C. Park. Gene selection using support vector machines with non-convex penalty. *Bioinformatics*, 22(1), 2006.

H. Zhao, C. J. Logothetis, and I. P. Gorlov. Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression. *Prostate Cancer and Prostatic Diseases*, 13:252–259, 2010.
Fig 3. Estimated classification accuracy for datasets predicting disease phenotypes. Classifiers were learned for datasets D1,…,D11 and performance was estimated by the average of ten runs of ten-fold cross validation. The box plots show the distribution of the 100 runs for each dataset. The number written close to every box represents the estimated accuracy of the classifier rate. Also, stars represent outliers.
Fig 4. Estimated classification accuracy for datasets predicting disease phenotypes. Classifiers were learned for datasets D12,...,D21 and the bottom diagram represents the average of the accuracies across all data sets. As can be seen, almost all of them perform similarly with the exception of TSP which lags the rest by 3%. On average, KTSP seems to perform with less dispersion and a slightly larger median accuracy.